公开(公告)号：US20250064902A1

公开(公告)日：2025-02-27

申请号：US18914723

申请日：2024-10-14

Applicant: AUROBAC THERAPEUTICS SAS

Inventor： Michael WITTEKIND ,  Raymond SCHUCH

IPC: A61K38/47 ,  A61K9/00 ,  A61K31/7036 ,  A61K38/12 ,  A61K38/16 ,  A61K38/46 ,  A61K45/06 ,  A61P31/04 ,  C12N9/36

Abstract: The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present. More specifically, the present disclosure describes that inhibition of antibiotics due to environmental factors, such as the presence of pulmonary surfactant in an organ or tissue such as the respiratory epithelium can be sidestepped or overcome and the effectiveness of the antibiotic in that milieu restored or augmented by co-administration of an antibiotic and a lysin.

公开(公告)号：US12226484B2

公开(公告)日：2025-02-18

申请号：US18487486

申请日：2023-10-16

Applicant: TRx Biosciences Limited

Inventor： John Brew ,  Daniel Gooding ,  Robin M. Bannister

IPC: A61K47/14 ,  A61K31/05 ,  A61K31/12 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/4453 ,  A61K31/496 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/58 ,  A61K31/7135 ,  A61K38/12 ,  A61K47/28

Abstract: The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C14-24 fatty acids, one or more free C14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.

公开(公告)号：US20250049883A1

公开(公告)日：2025-02-13

申请号：US18721128

申请日：2022-12-16

Applicant: The CGP Lab Limited

Inventor： Jian GUAN

IPC: A61K38/12 ,  A61K9/48 ,  A61K38/01 ,  G01N33/68

Abstract: Described herein are improvements relating to IGF-1 function analysis, adjustment and its application in disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) and/or cGP/IGF-1 molar ratio as the plasma biomarker for prediction of risk and recovery of non-neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing animal, marine or fungal based material such as concentrate/extract of hydrolysed bovine collagen and marine collagen, mushroom and seaweed along with plant-based cGPMAX™ for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 molar ratio along with a means to adjust and normalise cGP and cGP/IGF-1 molar ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data. Supplementation of bovine collagen formulated cGPMAX™ effectively improved the sensory function in patients with diabetic neuropathy.

公开(公告)号：US12221495B2

公开(公告)日：2025-02-11

申请号：US15122753

申请日：2016-05-27

Applicant: IGISU Co., Ltd.

Inventor： Kyoko Endo ,  Yori Endo

IPC: A61K38/03 ,  A61K8/64 ,  A61K38/10 ,  A61K38/12 ,  A61P17/14 ,  A61Q5/02 ,  A61Q5/12 ,  A61Q7/00 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/02 ,  A61Q19/04 ,  A61Q19/06 ,  A61Q19/08 ,  A61Q19/10 ,  C07K4/00 ,  C07K7/08 ,  C07K7/64 ,  A61K38/00

Abstract: The present invention is aimed for providing a novel peptide with a high drug efficacy and strong effect, a medicament or external preparation comprising it, specifically a prophylactic or therapeutic for dermatitis, rhinitis or alopecia, or a hair growth stimulant, a hair growing agent, an antipruritic or a skin-care product. The present invention achieved said aim by providing a cyclic peptide having an amino acid sequence expressed by the Formula I or a derivative thereof or a pharmaceutically acceptable salt thereof, wherein the amino acid sequence does not have a peptide bond that is not between the amino acids constituting the amino acid sequence.

公开(公告)号：US20250026816A1

公开(公告)日：2025-01-23

申请号：US18713540

申请日：2022-11-25

Applicant: KYMAB LIMITED

Inventor： Stephen REECE ,  Aisha KRISHNA ,  Siobhan O'LEARY ,  Josefin BARTHOLDSON SCOTT ,  Simon WATSON ,  Stephen BAKER

IPC: C07K16/12 ,  A61K31/407 ,  A61K38/12 ,  A61K39/00

Abstract: The present invention relates to antibodies that bind Acinetobacter baumannii, and their use in the diagnosis of, and the prevention and treatment of, bacterial infection caused by Acinetobacter baumannii. In particular, the present invention relates to monoclonal antibodies that specifically bind at the bacterial wall of Acinetobacter baumannii bacteria, such as on, e.g., living bacteria.

公开(公告)号：US20250011792A1

公开(公告)日：2025-01-09

申请号：US18709695

申请日：2022-11-30

Applicant: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  FONDATION IMAGINE ,  UNIVERSITÉ PARIS CITÉ ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Olivier HERMINE ,  Mirjana WEIMERSHAUS ,  Thiago TROVATI MACIEL ,  Peter VAN ENDERT ,  Michael DUSSIOT ,  Rachel RIGNAULT-BRICARD ,  Caroline CARVALHO

IPC: C12N15/113 ,  A61K31/351 ,  A61K31/381 ,  A61K31/4433 ,  A61K31/4709 ,  A61K38/07 ,  A61K38/12

Abstract: Upon activation, mast cells rapidly release preformed inflammatory mediators from large cytoplasmic granules via regulated exocytosis. This acute degranulation is followed by a late activation phase involving synthesis and secretion of cytokines, growth factors and other inflammatory molecules via the constitutive pathway that remains ill-defined. Here the inventors describe a role for an insulin-responsive vesicle-like endosomal compartment, marked by insulin-regulated aminopeptidase (IRAP), in the secretion of TNF-α and IL-6 in mast cells and macrophages. IRAP-deficient mice are protected from TNF-dependent kidney injury and inflammatory arthritis. In the absence of IRAP, TNF fails to be efficiently exported from the Golgi. Chemical targeting of IRAP+ endosomes reduced pro-inflammatory cytokine secretion thereby highlighting this compartment as a promising target for the therapeutic control of inflammation. Thus the present invention relates to the use of IRAP inhibitors for the treatment of inflammatory diseases

公开(公告)号：US20250011366A1

公开(公告)日：2025-01-09

申请号：US18690563

申请日：2022-09-08

Applicant: The Regents of the University of California

Inventor： Chelsea R. Jones ,  James S. Nowick

IPC: C07K7/56 ,  A61K38/12 ,  A61P31/04

Abstract: Prodrugs of antibiotic teixobactin, methods of their synthesis, and methods of their use as antimicrobial treatments are described. The teixobactin prodrugs incorporate one or more O-acyl linkages. The O-acyl linkages can be utilized in substitution of amide peptide bonds between an amino acid containing an alcohol side chain and the immediately preceding amino acid.

公开(公告)号：US12187770B2

公开(公告)日：2025-01-07

申请号：US17232145

申请日：2021-04-15

Applicant: Hangzhou Huibo Science and Technology Co., Ltd

Inventor： Yi Liu ,  Zhen Lin ,  Gang Wu

IPC: A61K38/12 ,  A61K38/18 ,  A61P19/08 ,  C07K1/107 ,  C07K1/16 ,  C07K14/51 ,  A61K38/00

Abstract: A cyclic peptide from a bone morphogenetic protein 2 (BrvIP2). The cyclic peptide from the novel BMP2 is selected from one of the following cyclic polypeptides: 1. a cyclic polypeptide having the sequence of CKIPKASSVPTELSAISMLYLGPGGDWIVAC (SEQ ID NO:1); and 2. a cyclic polypeptide of which the sequence has an 80% homology with the sequence defined in item 1. A preparation method for the cyclic peptide from the novel Blv1P2, and an application thereof in the preparation of the composite material for promoting the repair of large-sized bone defects.

公开(公告)号：US20250000936A1

公开(公告)日：2025-01-02

申请号：US18690607

申请日：2022-09-09

Applicant: Apellis Pharmaceuticals, Inc.

Inventor： Cedric Francois ,  Pascal Deschatelets ,  Federico Grossi

IPC: A61K38/12 ,  A61K9/00 ,  A61K45/06 ,  A61K47/60 ,  A61P27/02

Abstract: Methods and compositions for treatment of geographic atrophy are described.

公开(公告)号：US20250000935A1

公开(公告)日：2025-01-02

申请号：US18262740

申请日：2021-05-27

Applicant: 1) Zhejiang Novus Pharmaceuticals Co., Ltd. ,  Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutica

Inventor： Xiying YUAN ,  Weibao WANG ,  Guofeng WU ,  Lili YE ,  Jiali WU ,  Jingjing CAI ,  Yibin PAN ,  Juan CHA ,  Zhongming GAO ,  Qiming SUN ,  Yimin HE ,  Zuoliang WANG ,  Jianhong PING

IPC: A61K38/12 ,  A61K9/00 ,  A61K9/16 ,  A61K9/19 ,  A61K47/02 ,  A61K47/12 ,  A61K47/24 ,  A61K47/26

Abstract: The present invention provides a high-stability daptomycin composition for injection and preparation method therefor and use thereof. The daptomycin composition for injection comprises daptomycin and a pharmaceutically acceptable carrier, and the pharmaceutically acceptable carrier contains a divalent metal salt, a pH regulator, and an osmotic pressure regulator; and the molar ratio of daptomycin to divalent metal salt in the daptomycin composition for injection is 1:1.0 to 1:3.5. The daptomycin composition for injection of the present invention significantly improves the stability of the preparation, facilitates the storage and transportation of the preparation at room temperature, and ensures the safety of drug use; And the preparation method of the present invention has advantages such as green environmental protection, suitability for industrialization.